TULAREMIA PROPHYLAXIS: NEW LIVE VACCINE STRAINS
Abstract
Previous studies on tularemia prophylaxis have established that live vaccine is far superior to killed vaccines for the immunization of animals and man. Forther investigation indicated, however, that recovery from tularemia provided the monkey even greater immunity. We postulated that a live vaccine prepared from an attenuated mutant selected from a highly virulent North American strain might afford even greater protection than our present vaccine, which contains a mutant derived from an Old World strain of relatively lower initial virulence. Of the several attenuated mutants of strain SCHU screened for immunogenicity, using the mouse and guinea pig as test animals, SCHU S1-11 offered greatest potential. Live vaccine prepared from this mutant was well tolerated by the monkey when administered intracutaneously or by acupuncture and provided as high a grade of immunity as LVS vaccine against an intradermal challenge of 25,000 cells of highly virulent strain SCHU S4. A subsequent study in man, however, indicated that SCHU S1-11 vaccinees were not more resistant to infection with strain SCHU S4 than LVS vaccinees.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jan 01, 1965
- Accession Number
- AD0456683
Entities
People
- Henry T. Eigelsbach
- Richard B. Hornick
- Ruth D. Herring
Organizations
- United States Army Biological Warfare Laboratories